Enbrel (Amgen) is expected to face US biosimilar competition from 2029. Court-upheld patents block approved biosimilars until April 2029.
Enbrel's US exclusivity date is based on settlement / court date. Litigation settlements or a court ruling fix the earliest US entry date, which makes it one of the firmer dates in this tracker. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Enbrel was selected for the Medicare Drug Price Negotiation Program. Its negotiated Medicare price takes effect in 2026, 67% below its list price. That is 3 years before US biosimilars can launch, so Medicare revenue comes under pressure first. The discount is measured against list price, before the rebates drugmakers already pay, and applies to Medicare only, so the revenue impact is smaller than the headline number.
Enbrel is 6.1% of Amgen's 2025 revenue ($2.2B of $36.8B). With Prolia, the drugs tracked here add up to 18% of Amgen's revenue losing US exclusivity by 2029.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Enbrel is highlighted.